Seizures - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Seizures - Pipeline Review, H2 2016

Seizures - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Seizures - Pipeline Review, H2 2016
Published Jul 20, 2016
214 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Seizures - Pipeline Review, H2 2016, provides an overview of the Seizures pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seizures
- The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects
- The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seizures

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seizures
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying

  
Source:
Document ID
GMDHC8290IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Seizures Overview121
Therapeutics Development132
  Pipeline Products for Seizures Overview131
  Pipeline Products for Seizures Comparative Analysis141
Seizures Therapeutics under Development by Companies153
Seizures Therapeutics under Investigation by Universities/Institutes181
Seizures Pipeline Products Glance194
  Late Stage Products191
  Clinical Stage Products201
  Early Stage Products211
  Unknown Stage Products221
Seizures Products under Development by Companies234
Seizures Products under Investigation by Universities/Institutes271
Seizures Companies Involved in Therapeutics Development2828
  Adamas Pharmaceuticals, Inc.281
  Advicenne291
  Alexza Pharmaceuticals, Inc.301
  Biscayne Pharmaceuticals, Inc.311
  Catalyst Pharmaceuticals, Inc.321
  Eisai Co., Ltd.331
  GW Pharmaceuticals Plc341
  INSYS Therapeutics, Inc.351
  Lotus Pharmaceutical Co., Ltd.361
  Marinus Pharmaceuticals, Inc.371
  Neurelis, Inc.381
  Novartis AG391
  OPKO Health, Inc.401
  Pfizer Inc.411
  PTC Therapeutics, Inc.421
  Sage Therapeutics, Inc.431
  SciFluor Life Sciences, LLC441
  Shire Plc451
  SK Biopharmaceuticals Co., Ltd.461
  Suda Ltd471
  Turing Pharmaceuticals AG481
  UCB S.A.491
  Ultragenyx Pharmaceutical Inc.501
  Upsher-Smith Laboratories, Inc.511
  Xenon Pharmaceuticals Inc.521
  XERIS Pharmaceuticals, Inc.531
  Zogenix, Inc.541
  Zynerba Pharmaceuticals, Inc.551
Seizures Therapeutics Assessment5613
  Assessment by Monotherapy Products561
  Assessment by Target574
  Assessment by Mechanism of Action614
  Assessment by Route of Administration652
  Assessment by Molecule Type672
Drug Profiles69127
  ADS-4101 Drug Profile691
  ADV-6208 Drug Profile701
  ADV-6770 Drug Profile711
  alprazolam Drug Profile722
  AMPX-0079 Drug Profile741
  ataluren Drug Profile758
  BIS-001 Drug Profile831
  brivaracetam Drug Profile844
  cannabidiol Drug Profile886
  cannabidiol Drug Profile942
  CCG-63802 Drug Profile961
  CHEC-9 Drug Profile971
  clobazam Drug Profile981
  CNSA-004 Drug Profile991
  CPP-115 Drug Profile1004
  CUR-1916 Drug Profile1041
  diazepam Drug Profile1052
  diazepam Drug Profile1071
  everolimus Drug Profile10811
  fenfluramine hydrochloride Drug Profile1193
  fosphenytoin sodium Drug Profile1221
  ganaxolone Drug Profile1235
  lacosamide Drug Profile1289
  levetiracetam Drug Profile1373
  levetiracetam ER Drug Profile1401
  lorazepam Drug Profile1411
  LSPGR-1 Drug Profile1421
  magnesium valproate hydrate Drug Profile1431
  MB-003 Drug Profile1441
  midazolam hydrochloride Drug Profile1453
  midazolam hydrochloride Drug Profile1481
  midazolam hydrochloride Drug Profile1491
  midazolam hydrochloride Drug Profile1501
  Oligonucleotide for Dravet Syndrome Drug Profile1511
  perampanel Drug Profile1527
  pregabalin Drug Profile1594
  SAGE-217 Drug Profile1632
  SAGE-689 Drug Profile1651
  selurampanel Drug Profile1661
  sepranolone Drug Profile1677
  SF-0034 Drug Profile1742
  Small Molecule for Stroke and Epilepsy Drug Profile1761
  Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile1771
  Small Molecule to Block Nav1.6 for Dravet Syndrome Drug Profile1781
  Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus Drug Profile1791
  Small Molecules for Seizure Disorders Drug Profile1801
  Small Molecules for Seizures Drug Profile1811
  TG-4155 Drug Profile1821
  TRP-001 Drug Profile1831
  TUR-004 Drug Profile1841
  TUR-005 Drug Profile1851
  UX-007 Drug Profile1865
  YKP-3089 Drug Profile1912
  ZYN-002 Drug Profile1933
Seizures Dormant Projects1963
Seizures Discontinued Products1991
Seizures Product Development Milestones20013
  Featured News &Press Releases2001
    Jul 04, 2016: UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy2001
    Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs2001
    Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs2011
    Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome2022
    Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures2041
    Jun 22, 2016: Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV2051
    Jun 16, 2016: Eisai Launches New Oral Suspension Formulation For Antiepileptic Drug Fycompa (Perampanel) In The United States2061
    Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures2061
    Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures2071
    Jun 13, 2016: Lotus ANDA Of Levetiracetam ER Tablets Has Been Officially Approved By US FDA2081
    Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome2081
    Jun 07, 2016: Sage Reports Positive Top-line Results from Phase 1 Clinical Program of SAGE-2172091
    May 31, 2016: BRIVIACT now available in U.S. pharmacies for epilepsy patients living with partial-onset seizures2101
    May 26, 2016: New epilepsy treatment BRIVLERA (brivaracetam) now available in Canada for patients with partial-onset seizures2111
    May 25, 2016: Eisai To Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) As Adjunctive Therapy For Partial-Onset And Generalized Tonic-Clonic Seizures In Japan2112
Appendix2132
  Methodology2131
  Coverage2131
  Secondary Research2131
  Primary Research2131
  Expert Panel Validation2131
  Contact Us2131
  Disclaimer2141

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Seizures - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Seizures-Pipeline-Review-H2-2016-2088-16253>
  
APA:
Global Markets Direct - Market Research. (2016). Seizures - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Seizures-Pipeline-Review-H2-2016-2088-16253>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.